KLOW peptide dosage literature: component half-lives, the 80 mg vial, and the inherent pharmacokinetic mismatch

Before the details

There is no validated human dose for KLOW peptide as a blend — no clinical trial has tested it, so no dose range has ever been measured or approved. What exists is a research-vial convention: 80 mg total, split roughly 50/10/10/10 mg across the four components.

The more significant finding from a pharmacokinetics perspective is that the four components clear the body at very different speeds. KPV and GHK-Cu are small tripeptides that break down quickly; BPC-157 is a larger peptide with a short but measurably longer presence; TB-500 is a medium-sized fragment whose behavior in humans has not been formally measured. Giving all four in one vial means the exposures will not overlap evenly — the fast-clearing peptides peak and fall before the slower ones have run their course.

This is a property of the blend's design, not a flaw in any single component. It is documented here because it is the most structurally important feature of KLOW as a co-formulation.

KLOW peptide dosage — the canonical vial composition

The most widely listed research-vial composition across independent compounders is:

• GHK-Cu: 50 mg (62.5% by mass)
• BPC-157: 10 mg (12.5% by mass)
• TB-500: 10 mg (12.5% by mass)
• KPV: 10 mg (12.5% by mass)
• Total: 80 mg

This is a research formulation convention, not a validated clinical dose. No pharmacopeial specification or FDA-approved product exists for this combination. Reconstitution is typically with bacteriostatic water for laboratory handling; the lyophilized blend is refrigerated post-reconstitution.

Component-level doses administered in the published research literature are listed below for reference. These are the doses used in specific experiments with specific species by specific routes — they are not recommendations for human administration.

KLOW dosage — component pharmacokinetics: the mismatch table

The four KLOW components have markedly different reported pharmacokinetic profiles. This is the central structural limitation of co-formulating them at a fixed dose ratio.

KPV (MW 342.44 Da, CAS 67727-97-3). The smallest peptide in the blend. PepT1-mediated transport into cells suggests rapid uptake and likely fast degradation; no validated half-life in plasma has been published in a dedicated KPV PK study. Based on di/tripeptide PK generally, clearance is expected to be rapid (minutes to low-single-digit hours).

GHK-Cu (MW 402.92 Da, CAS 89030-95-5). Rat plasma HPLC data show free GHK is rapidly degraded to the dipeptide histidyl-lysine (HK) after intravenous administration, with detection limits of 50 ng/mL for GHK and 15 ng/mL for HK ^[8]. No validated human half-life exists. The copper moiety may behave differently from the peptide backbone and is not fully characterized in the context of rapid GHK degradation.

BPC-157 (MW 1419.53 Da, CAS 137525-51-0). An elimination half-life of under approximately 30 minutes has been reported in rat pharmacokinetic studies, making it the formally-characterized PK anchor for the blend; it clears faster than most peptides of its size suggest. At 2025 IV human doses of 10–20 mg in two adults, BPC-157 was detectable without adverse events ^[6], but no human half-life has been formally published.

TB-500 (Ac-LKKTETQ, MW 889.02 Da). Detection in equine plasma/urine at LOD 0.01–0.02 ng/mL has been reported in a doping-control context ^[9], establishing an analytical presence window, but no validated human or rat PK half-life study has been published for the TB-500 fragment specifically.

The mismatch. A single co-formulated dose cannot hold KPV, GHK-Cu, BPC-157, and TB-500 at matched tissue exposures simultaneously. The two tripeptides clear faster than the BPC-157; TB-500's clearance relative to the others is uncharacterized. Whether timed or split dosing of the components would provide more concordant exposures has not been studied for KLOW.

KLOW peptide dosage and frequency — research context only

Doses recorded in the component literature:

• KPV: 10 nM in human intestinal epithelial cell cultures; 100 microM in drinking water in murine colitis models ^[3]. No human dose.
• GHK-Cu: Low-nanomolar concentrations in cell culture (transcriptomic studies ^[5]); topical formulations in placebo-controlled cosmetic trials ^[4]; 0.5 mg/cm^3 in liposomal formulations for skin delivery ^[13]. No approved systemic human dose.
• BPC-157: 10 microg, 10 ng, or 10 pg per rat IP in the Achilles tendon model ^[2]; 10–20 mg IV in 250 cc saline in the 2025 human safety pilot ^[6] — a safety tolerability assessment in two adults, not a dosing protocol.
• TB-500 / Tbeta4: 10 pg sufficed to stimulate keratinocyte migration in vitro; topical and IP routes were studied in rat wound models ^[1]. No validated human dose for the TB-500 fragment.

No human KLOW dose recommendation exists in the peer-reviewed literature. The component doses above are recorded for research transparency, not as a guide for administration.

Routes studied in the component literature

Component studies have used:

• Subcutaneous / intraperitoneal injection (BPC-157, TB-500 / Tbeta4 rodent studies)
• Intravenous infusion (BPC-157 human pilot ^[6]; GHK rat plasma PK ^[8])
• Oral / targeted delivery (KPV in DSS mouse colitis ^[3][11][15]; BPC-157 oral in some rodent work)
• Topical (GHK-Cu cosmetic studies ^[4][10][13]; Tbeta4 wound topical application ^[1])

The KLOW research vial is lyophilized for subcutaneous injection in research settings. The route-efficacy data supporting different injection sites come from single-component studies, not from the blend.

Stability and reconstitution notes

Lyophilized peptide blends are typically reconstituted with bacteriostatic water and refrigerated after reconstitution. A theoretical compatibility consideration for KLOW specifically: copper(II) in GHK-Cu can participate in redox chemistry, and co-dissolving it with three other peptides in one vial raises a theoretical oxidation or compatibility concern. This has not been formally characterized for the KLOW mixture; it is noted here because the chemistry is established and the interaction in the specific blend is not.